Product Development Pipeline

Silver Creek is pursuing drug development programs for a range of diseases in which growth factor signaling plays a critical role in promoting cell and tissue repair. Our near-term focus is on the development of SGF-1, a Smart Growth Factor™ that selectively accumulates in tissue where apoptosis (programmed cell death) is occurring.

In preclinical in vivo studies, SGF-1 demonstrated:

  • Reduced cardiac cell death following ischemia reperfusion (I/R) injury
  • Proof of concept in models of acute myocardial infarction (AMI)
  • Potential efficacy in stroke/brain injury

Our lead SGF-1 product candidate targets treatment of acute myocardial infarction (AMI). In addition, we are evaluating SGF-1 in acute kidney injury  (AKI) and in traumatic brain injury (TBI).

Smart Growth Factor™ technology is broadly applicable. In addition to treating heart failure, kidney disease, and brain injury, SGFs have the potential to treat skeletal muscle indications, peripheral neuropathies, and liver disease.

Product Programs
 
Indication(s)
 
Discovery
Lead
Optimization
 
IND-Enabling
 
Phase 1
SGF-1
Acute myocardial infarction (AMI)
Acute kidney infection (AKI)
Traumatic brain Injury (TBI)
SGF-2
Congestive heart failure
SGF-3
Diabetic nephropathy
Focal segmental glomerulosclerosis

Initial Therapeutic Focus Areas


Acute Myocardial Infarction (AMI)

AMI is a frequently occurring, life-threatening condition. While a substantial proportion of AMI cases are successfully treated by rapid implantation of a coronary stent at angioplasty combined with drug treatment, a large proportion of AMI patients (as high as 45%) reach the angioplasty lab late or have a large or complicated infarct where treatment leaves substantial damage to the myocardium, eventually leading to heart failure.

In preclinical studies of SGF-1 in small and large animal models of AMI, SGF-1 substantially reduced cell death and myocardial damage. We believe that SGF-1 is a potentially beneficial treatment to be administered in addition to the current standard of care, with the aim of reducing myocardial damage and post-AMI heart failure.

Acute Kidney Injury (AKI)
Approximately 60% of patients suffering from AKI in the U.S. die every year as a result of very low blood pressure (“shock”) or toxins such as cancer chemotherapy or intravenous radiographic contrast agents. At present, there are no therapies available to treat this condition. Insulin-like growth factor 1 (IGF1) has been a candidate therapy for AKI for many years, but clinical trials in which IGF1 was tested in humans were unsuccessful due to its short half-life. We believe that the long half-life and cell selectivity of our medicine, SGF-1, circumvents these difficulties.

Traumatic Brain Injury (TBI)
TBI represents a significant unmet medical need in both civilian and military populations. In the U.S., brain injuries serious enough to result in hospitalization or death are projected to affect 10 million people annually. Approximately 1.7 million people in the U.S. suffer TBI annually and, according to the U.S. Department of Defense, 200,000 service personnel have suffered serious TBIs in the last 12 years.

 


[1] Murray CJ, Lopez AD. Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for Over 200 Conditions. Boston: Harvard School of Public Health; 1996.

[2] NIH Database Will Speed Research Toward Better Prevention, Diagnosis, and Treatment of Traumatic Brain Injury. August 29, 2011.